Abstract
SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have